ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.39
+0.57 (7.29%)
At close: Mar 13, 2026, 4:00 PM EDT
8.40
+0.01 (0.12%)
After-hours: Mar 13, 2026, 7:59 PM EDT
ImmunityBio Revenue
In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. ImmunityBio had revenue of $38.29M in the quarter ending December 31, 2025, with 406.95% growth.
Revenue (ttm)
$113.29M
Revenue Growth
+668.31%
P/S Ratio
76.14
Revenue / Employee
$163,948
Employees
691
Market Cap
8.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1,000.00 | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Axsome Therapeutics | 638.50M |
| Krystal Biotech | 389.13M |
| Cytokinetics | 88.04M |
| Praxis Precision Medicines | 7.46M |
IBRX News
- 1 day ago - Why Is ImmunityBio Stock Soaring On Friday? - Benzinga
- 1 day ago - ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors - Business Wire
- 5 days ago - ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug - Benzinga
- 5 days ago - ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data - PRNewsWire
- 10 days ago - ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026 - Business Wire
- 16 days ago - ImmunityBio Investors Rally Behind Cancer Trial Milestone - Benzinga
- 16 days ago - ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ - Business Wire